
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem is a poised for growth in the oncology market, with a focus on treating LGSOC and pancreatic cancer and potential for their drug combination to become the new standard of care. Their drug VS-7375 has shown potential for maximal tumor regression and partnerships and expected peak sales further support their potential for success. Investors should keep an eye on upcoming data releases and trials, as well as competition in the market.
Bears say
Verastem is a late-stage development biopharmaceutical company focused on novel anticancer agents that inhibit critical signaling pathways in cancer, particularly through RAF/MEK and FAK inhibition, but its preliminary efficacy update for these drugs in 2H26 is expected to be limited and may only lead to a modest increase in stock price. Additionally, although darovonrasib and VS-7375 show strong potential in PDAC and NSCLC, there are limitations such as rash burden and GI toxicity which may hinder their success in combination therapies. Furthermore, as a clinical-stage company, Verastem faces a range of standard risks in the biopharmaceutical industry which could affect its development, regulatory approval, and commercial success.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares